Moderate to severe atopic dermatitis.
Tacrolimus is a macroiide immunomodulator produced by fungus, Streptomyces tsukubaensis. It has been demonstrated that Tacrolimus inhibits T-lymphocyte activation by first binding to an intracellular protein, FKBP-12. A complex of Tacrolimus-FKBP-12, calcium, calmodulin, and calcineurin is then formed and the phosphatase activity of calcineurin is inhibited. This leads to a general decrease in the entire inflammatory cascade.
Twice daily for one week until clearing of signs & symptoms of atopic dermatitis.
Formal topical drug interaction studies with Tacrolimus ointment have not been conducted. The concomitant administration of known CYP3A4 inhibitors in patients with widespread and/or erythrodermic disease should be done with caution. Some examples of such drugs are erythromycin, itraconazole, ketoconazole, fluconazole, calcium channel blockers and cimetidine.
Hypersensitivity, Netherton’s Syndroms, generalized erythroderma.
Skin Burning, pruritus, allergic reaction, anaphylactoid reaction, angioedema, anorexia, anxiety.
Caution should be taken during pregnancy & lactation.
Tacrolimus ointment is not for oral use. Accidental oral ingestion of Tacrolimus ointment may lead to adverse effects associated with systemic administration of Tacrolimus. If oral ingestion occurs, medical advice should be sought.
Do not store above 30°C. Keep away from light and out of the reach of children.
.png&w=384&q=75)